In a move to strengthen its neurology franchise, Allergan has agreed to acquire MAP Pharmaceuticals, developer of the acute migraine drug Levadex® (dihydroergotamine) inhalation aerosol, in a deal that values the company at approximately US$958 M. Levadex is currently awaiting a regulatory decision from the US FDA with a PDUFA date of 15 April 2013. Allergan markets Botox® (onabotulinumtoxinA) for the prophylactic management of chronic migraine and in 2011 the company agreed to co-promote Levadex to neurologists and pain specialists in the US.